Abstract
Through unintentional discovery, monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs) were the first antidepressant classes to be used clinically and have been widely available for over half a century. From the 1950s to the 1980s, these two classes of antidepressants were the sole antidepressant tools available to psychiatrists. With the advent of the selective serotonin reuptake inhibitors (SSRIs) in the 1980s and 1990s, the prescribing of the MAOIs and TCAs has fallen significantly worldwide. In this chapter, we take a closer look at the arc of MAOI discovery and clinical use, and how these two classes of drugs compare to each other. This is important because relatively few studies compare these older classes of drugs to the newer classes of antidepressants. Finally, we argue that TCAs, and particularly MAOIs, should continue to play an important role in the modern treatment of depression, especially in the treatment-resistant patient.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders. American Psychiatric Association, Washington
Arroll B, Macgillivray S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I (2005) Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 3(5):449–456
Balon R, Mufti R, Arfken CL (1999) A survey of prescribing practices for monoamine oxidase inhibitors. Psychiatr Serv 50(7):945–947
Birkenhager TK, van den Broek WW, Mulder PG, Bruijn JA, Moleman P (2004) Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients. J Clin Psychiatry 65(11):1505–1510
Clary C, Mandos LA, Schweizer E (1990) Results of a brief survey on the prescribing practices for monoamine oxidase inhibitor antidepressants. J Clin Psychiatry 51(6):226–231
Conway CR, Gebara MA, Walker MC, Lessov-Schlaggar CN, Janski AM, Chibnall JT, Cristancho P, Sheline YI, Gott BM, Svrakic DM (2015) Clinical characteristics and management of treatment-resistant depression. J Clin Psychiatry 76(11):1569–1570
Davidson JR, McLeod MN, Turnbull CD, Miller RD (1981) A comparison of phenelzine and imipramine in depressed inpatients. J Clin Psychiatry 42(10):395–397
Hillhouse TM, Porter JH (2015) A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol 23(1):1–21
Himmelhoch JM, Fuchs CZ, Symons BJ (1982) A double-blind study of tranylcypromine treatment of major anergic depression. J Nerv Ment Dis 170(10):628–634
Hori A (1998) Pharmacotherapy for personality disorders. Psychiatry Clin Neurosci 52(1):13–19
Hypertensive crisis and monoamine oxidase inhibitors (1963) Can Med Assoc J 89(22):1149–1150
Krishnan KR (2007) Revisiting monoamine oxidase inhibitors. J Clin Psychiatry 68(Suppl 8):35–41
Kuhn R (1958) The treatment of depressive states with G 22355 (imipramine hydrochloride). Am J Psychiatry 115(5):459–464
Lecrubier Y, Guelfi JD (1990) Efficacy of reversible inhibitors of monoamine oxidase-A in various forms of depression. Acta Psychiatr Scand Suppl 360:18–23
Liebowitz MR, Quitkin FM, Stewart JW, Mcgrath PJ, Harrison W, Rabkin J, Tricamo E, Markowitz JS, Klein DF (1984) Phenelzine-V imipramine in atypical depression – a preliminary-report. Arch Gen Psychiatry 41(7):669–677
Little A (2009) Treatment-resistant depression. Am Fam Physician 80(2):167–172
Martin ME (1963) A comparative trial of imipramine and phenelzine in treatment of depression. Br J Psychiatry 109(459):279–285
Paykel ES (1995) Clinical efficacy of reversible and selective inhibitors of monoamine oxidase A in major depression. Acta Psychiatr Scand Suppl 386:22–27
Quitkin F, Rifkin A, Klein DF (1979) Monoamine oxidase inhibitors. A review of antidepressant effectiveness. Arch Gen Psychiatry 36(7):749–760
Ramachandraih CT, Subramanyam N, Bar KJ, Baker G, Yeragani VK (2011) Antidepressants: from MAOIs to SSRIs and more. Indian J Psychiatry 53(2):180–182
Robinson DS, Nies A, Ravaris CL, Ives JO, Bartlett D (1978) Clinical pharmacology of phenelzine. Arch Gen Psychiatry 35(5):629–635
Rowan PR, Paykel ES, Parker RR (1982) Phenelzine and amitriptyline: effects on symptoms of neurotic depression. Br J Psychiatry 140:475–483
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163(11):1905–1917
Sandler M (1990) Monoamine oxidase inhibitors in depression: history and mythology. J Psychopharmacol 4:136–139
Sathyanarayana Rao TS, Yeragani VK (2009) Hypertensive crisis and cheese. Indian J Psychiatry 51(1):65–66
Shulman KI, Walker SE (1999) Refining the MAOI diet: tyramine content of pizzas and soy products. J Clin Psychiatry 60(3):191–193
Shulman KI, Fischer HD, Herrmann N, Huo CY, Anderson GA, Rochon PA (2009) Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: a population-based cohort study of older adults. J Clin Psychiatry 70(12):1681–1686
Stahl SM, Felker A (2008) Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr 13(10):855–870
Thase ME, Frank E, Mallinger AG, Hamer T, Kupfer DJ (1992) Treatment of imipramine-resistant recurrent depression, III: efficacy of monoamine oxidase inhibitors. J Clin Psychiatry 53(1):5–11
Thase ME, Trivedi MH, Rush AJ (1995) MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 12(3):185–219
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Chockalingam, R., Gott, B.M., Conway, C.R. (2018). Tricyclic Antidepressants and Monoamine Oxidase Inhibitors: Are They Too Old for a New Look?. In: Macaluso, M., Preskorn, S. (eds) Antidepressants. Handbook of Experimental Pharmacology, vol 250. Springer, Cham. https://doi.org/10.1007/164_2018_133
Download citation
DOI: https://doi.org/10.1007/164_2018_133
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-10948-6
Online ISBN: 978-3-030-10949-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)